Folpet is a broad-spectrum fungicide with the chemical name N-(trichloromethylthio)phthalimide. It is synthesized by the reaction of phthalimide with trichloromethanesulfenyl chloride. Folpet has contact and protective activity against a wide range of fungal diseases, including powdery mildew, leaf spots, and fruit rots. It is commonly used in agriculture to protect crops such as grapes, strawberries, and tomatoes. Folpet is known to inhibit fungal spore germination and mycelial growth. It is studied due to its efficacy against a broad range of fungal pathogens, its relatively low mammalian toxicity, and its availability as a cost-effective fungicide. However, folpet has also been shown to have potential environmental impacts, including toxicity to aquatic organisms and potential residues in food crops. Therefore, its use is subject to regulatory restrictions and monitoring.'
folpet : A member of the class of phthalimides that is phthalimide in which the hydrogen attached to the nitrogen is replaced by a trichloromethylthio group. An agricultural fungicide, it has been used to control mildew, leaf spot, and other diseases in crops sice the 1950s. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 8607 |
CHEMBL ID | 1883819 |
CHEBI ID | 82019 |
SCHEMBL ID | 19853 |
MeSH ID | M0046303 |
Synonym |
---|
AC-997 |
133-07-3 |
n-(trichloromethylthio)phthalimide |
phthalimide, n-((trichloromethyl)thio)- |
murphy's rose fungicide |
n-(trichlormethylthio)phthalimide |
fungitrol ii |
ortho phaltan 50w |
spolacid |
orthophaltan |
ent 26539 |
folpan |
trichlormethylthioimid kyseliny ftalove [czech] |
1h-isoindole-1,3(2h)-dione, 2-((trichloromethyl)thio)- |
epa pesticide chemical code 081601 |
cosan i |
phthaltan |
hsdb 2651 |
thiophal |
phaltan |
folpet [ansi:bsi:iso] |
ftalan |
trichloromethylthiophthalimide |
acryptan |
folpel |
folpel [french] |
brn 0193373 |
faltex |
folnit |
faltan |
ccris 1036 |
n-(trichloromethanesulphenyl)phthalimide |
n-(trichlor-methylthio)-phthalamid [german] |
vinicoll |
caswell no. 464 |
fungitrol |
ai3-26539 |
fungitrol 11 |
2-((trichloromethyl)thio)-1h-isoindole-1,3(2h)-dione |
intercide tmp |
troysan anti-mildew o |
einecs 205-088-6 |
phthalimide, n-[(trichloromethyl)thio]- |
2-[(trichloromethyl)thio]-1h-isoindole-1,3(2h)-dione |
phthalic acid,imide,n-trichloromethyl sulfenyl |
1h-isoindole-1,3(2h)-dione, 2-[(trichloromethyl)thio]- |
inchi=1/c9h4cl3no2s/c10-9(11,12)16-13-7(14)5-3-1-2-4-6(5)8(13)15/h1-4 |
folpet |
NCGC00168313-01 |
2-(trichloromethylsulfanyl)isoindole-1,3-dione |
n-(trichloromethyl)thiophthalimide |
FT-0659392 |
n-(trichloromethylmercapto)phthalimide |
2-(trichloromethylthio)isoindole-1,3-dione |
A806547 |
NCGC00168313-03 |
NCGC00168313-02 |
C18860 |
dtxsid0021385 , |
cas-133-07-3 |
dtxcid101385 |
tox21_301077 |
NCGC00254978-01 |
NCGC00259536-01 |
tox21_201987 |
n-(trichlor-methylthio)-phthalamid |
x5nfk36917 , |
trichlormethylthioimid kyseliny ftalove |
unii-x5nfk36917 |
5-21-11-00118 (beilstein handbook reference) |
trifol |
acryptane |
cosan t |
ryl |
dipet |
sanfol |
orthofaltan 50 |
phaltane |
n-[(trichloromethyl)thio]phthalimide |
AKOS015895774 |
folpet-d4 |
2-((trichloromethyl)thio)isoindoline-1,3-dione |
SCHEMBL19853 |
CHEMBL1883819 |
chebi:82019 , |
folpet [iso] |
folpet [mi] |
folpet [hsdb] |
2-[(trichloromethyl)sulfanyl]-1h-isoindole-1,3(2h)-dione |
n-(trichloromethanesulfenyl)phthalimide |
2-[(trichloromethyl)sulfanyl]-1h-isoindole-1,3(2h)-dione # |
folpex |
trichloromethyl(thio)phthalimide |
2-[(trichloromethyl)sulfanyl]-2,3-dihydro-1h-isoindole-1,3-dione |
folpet, pestanal(r), analytical standard |
folpet 100 microg/ml in cyclohexane |
phalton |
2-[(trichloromethyl)thio]-1h-isoindole-1,3(2h)-dione, 9ci |
n-[(trichloromethyl)thio]-phthalimide |
n-((trichloromethyl)thio)-phthalimide |
J-006303 |
folpet (fungicide) |
2-(trichloromethylthio)isoindoline-1,3-dione |
Q426485 |
CS-0013944 |
D95854 |
HY-B1878 |
2-((trichloromethyl)thio)-1h-isoindole-3(2h)-dione |
folpet 100 microg/ml in acetone |
folpet 1000 microg/ml in acetone |
AS-80226 |
folpet 10 microg/ml in cyclohexane |
Folpet is a phthalimide type of fungicide. It has been used to control several crop diseases.
Excerpt | Reference | Relevance |
---|---|---|
"Folpet is a phthalimide type of fungicide and has been used to control several crop diseases. " | ( Folpet induces mitochondrial dysfunction and ROS-mediated apoptosis in mouse Sertoli cells. Ham, J; Lim, W; Song, G; Yun, BH, 2021) | 3.51 |
Folpet treatment decreased cell proliferation and promoted apoptosis with cell cycle arrest. Folpet treatment caused apoptosis, dysregulated intracellular calcium levels, and mitochondrial membrane potential.
Excerpt | Reference | Relevance |
---|---|---|
"Folpet treatment decreased cell proliferation and promoted apoptosis with cell cycle arrest." | ( Reproductive toxicity of folpet through deregulation of calcium homeostasis in porcine trophectoderm and luminal epithelial cells during early pregnancy. Bae, H; Lim, W; Park, S; Song, G; Yun, BH, 2021) | 1.65 |
"Folpet treatment caused apoptosis, dysregulated intracellular calcium levels, and mitochondrial membrane potential, leading to cell death." | ( Folpet promotes apoptosis of bovine mammary epithelial cells via disruption of redox homeostasis and activation of MAPK cascades. An, G; Lim, W; Park, J; Song, G, 2023) | 3.07 |
LD50 of folpet in mammals, birds, and fish is relatively high. Results show significant differences between two slightly toxic products.
Excerpt | Reference | Relevance |
---|---|---|
"An ip LD50 value (68 mg/kg) for folpet, a widely used fungicide, was determined using adult male Sprague-Dawley rats." | ( Hepatotoxicity of orally and intraperitoneally administered folpet in male rats. Ashley, WM; Dalvi, RR; Smith, RE, ) | 0.66 |
" In vineyards where mancozeb had commonly been used over years, this fungicide is generally slightly toxic, in some cases moderately toxic and rarely toxic." | ( Side effects of mancozeb on Typhlodromus pyri (Acari: Phytoseiidae) in vineyards: results of multi-year field trials and a laboratory study. Auger, P; Duriatti, A; Kreiter, S; Mattioda, H, 2004) | 0.32 |
"Results obtained with the ANPP/CEB guideline allow the demonstration of significant differences between two slightly toxic products, a dichlofluanid 500 g kg(-1) kWP (Euparen) 50WP) and a quinoxyfen 250 g L(-1) SCC (Legend), and a highly toxic cymoxanil 60/mancozeb 200/folpet 275 g kg(-1) WP [Remiltine F Pepite) (RFP)], on the basis of bioassays conducted in the laboratory." | ( Suitability of two laboratory testing methods to evaluate the side effects of pesticides on Typhlodromus pyri Scheuten (Acari: Phytoseiidae). Auger, P; Bonafos, R; Guichou, S; Kreiter, S, 2008) | 0.52 |
" The LD50 of folpet in mammals, birds, and fish is relatively high." | ( Reproductive toxicity of folpet through deregulation of calcium homeostasis in porcine trophectoderm and luminal epithelial cells during early pregnancy. Bae, H; Lim, W; Park, S; Song, G; Yun, BH, 2021) | 1.29 |
" Therefore, temperature also affects metabolic rates and thus processes that might enhance or reduce toxic effects." | ( Low temperatures lead to higher toxicity of the fungicide folpet to larval stages of Rana temporaria and Bufotes viridis. Brühl, CA; Leeb, C; Schuler, L; Theissinger, K, 2022) | 0.97 |
Excerpt | Reference | Relevance |
---|---|---|
" The obtained results show that the DLLME combined with GC-ECD can satisfy the requirements for the determination of fungicides in apple samples." | ( Analysis of captan, folpet, and captafol in apples by dispersive liquid-liquid microextraction combined with gas chromatography. Ma, J; Wang, J; Wang, M; Wang, O; Wang, Z; Xi, G; Zang, X, 2008) | 0.67 |
Excerpt | Reference | Relevance |
---|---|---|
" Antagonism between Cu and folpet could not be explained by a reduced bioavailability of Cu since concentration of free copper in the mixture did not depend on the presence of folpet." | ( Toxic responses and catalase activity of Lemna minor L. Exposed to folpet, copper, and their combination. Couderchet, M; Teisseire, H; Vernet, G, 1998) | 0.83 |
Excerpt | Relevance | Reference |
---|---|---|
" These results suggest that the choice of the fungicide partner and its dosage in the mixture can significantly affect the success of QoI resistance management strategies under practical conditions." | ( Effect of dose rate and mixtures of fungicides on selection for QoI resistance in populations of Plasmopara viticola. Deparis, F; Genet, JL; Jaworska, G, 2006) | 0.33 |
"1 μmol/L, along with urine samples of volunteers dosed with folpet, and of exposed workers." | ( Gas-chromatography mass-spectrometry determination of phthalic acid in human urine as a biomarker of folpet exposure. Berode, M; Berthet, A; Bouchard, M, 2011) | 0.83 |
Role | Description |
---|---|
antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
organosulfur compound | An organosulfur compound is a compound containing at least one carbon-sulfur bond. |
phthalimide fungicide | A dicarboximide fungicide whose structure contains a phthalimide derivative. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 17.8376 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 33.3284 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.5855 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 13.2281 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 13.2281 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.6074 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 14.9616 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743054; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 25.6271 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 27.5130 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 28.7509 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533; AID720691; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 21.6141 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 18.1445 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 43.5479 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 42.1442 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 4.5450 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 29.2246 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID588513; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 29.7009 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743212; AID743215; AID743227 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 31.9565 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743140; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 28.6604 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743222; AID743223; AID743241 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 3.9380 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 13.9037 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 3.6532 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 30.1060 | 0.1549 | 17.8702 | 43.6557 | AID1346877 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 43.3292 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 16.0550 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 11.0629 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 5.3132 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743066; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 25.1944 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 35.5140 | 0.0006 | 27.2152 | 1,122.0200 | AID720636; AID743202; AID743219 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 18.4134 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 8.6167 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743; AID720552 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 18.4134 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 68.5896 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
Ataxin-2 | Homo sapiens (human) | Potency | 68.5896 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 11 (15.28) | 18.7374 |
1990's | 7 (9.72) | 18.2507 |
2000's | 16 (22.22) | 29.6817 |
2010's | 28 (38.89) | 24.3611 |
2020's | 10 (13.89) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (49.38) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (2.50%) | 5.53% |
Reviews | 5 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 73 (91.25%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |